Publication

Article

BioPharm International

BioPharm International-06-02-2003
Volume2003 Supplement
Issue 1

Part 6: Inactivation Methods Grouped by Virus

Author(s):

Gail Sofer,Jeri Ann Boose

by Gail Sofer, BioReliance, Dorothy C. Lister, and Jeri Ann Boose

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue
Part 1: Skin, Bone, and Cells
BioPharm International's Virus Inactivation Series: A Preface
Part 4: Culture Media, Biotechnology Products, and Vaccines
Inactivation of Viruses: An Introduction to the Series
Part 3b: Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)
Part 6: Inactivation Methods Grouped by Virus

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Quality Control Laboratory medicine. Chromatograph operation. A woman makes an analysis on a gas chromatograph. Development of a new vaccine against the covid-19 virus. | Image Credit: © neznamov1984 - © neznamov1984 - stock.adobe.com
August 15th 2025

ElevateBio BaseCamp Achieves First Multi-Modality ICMC Certification in Commercial CGT Manufacturing

Feliza Mirasol
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 15th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Businessman look at higher career barriers ambitious to overcome | Image Credit: © Lerbank-bbk22 - stock.adobe.com
August 15th 2025

Biopharma Development Hurdles: Lessons from Vedanta’s Live Bacteria Cocktail Failure

Christopher Cole
Mastering Antibody-Drug Conjugates
August 15th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Site Logo
August 15th 2025

A Strategic Manufacturing Partner

Emergent
Background with viruses. Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy. A model is built using data of viral macromolecular structure from Protein Data Bank (PDB 3NG9) | Image credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
August 15th 2025

ProBio Launches End-to-End AAV Production at NJ Manufacturing Site

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.